BRD4 and ameloblastoma: BET inhibitors are currently used to treat patients with NUT midline carcinoma, driven by a BRD4-NUT fusion oncoprotein [48], and are a potential treatment avenue for tumors that have aberrant BET protein or gene function, such as ameloblastoma [49].